Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin

    loading  Checking for direct PDF access through Ovid



Cross-sectional studies suggest insulin resistance is strongly associated with hepatic steatosis and fibrosis in patients with chronic hepatitis C (CHC), which might affect the efficacy of antiviral therapy.


To investigate retrospectively the impact of insulin resistance on treatment response in Chinese genotype 1 CHC patients receiving a 24-week course therapy with peginterferon α-2b/ribavirin.


A total of 133 biopsy-proven CHC patients were enrolled for analyses. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR). Hepatic fibrosis was graded by the METAVIR scoring system.


Mean HOMA-IR progressively elevated along with the severity of hepatic fibrosis (F1–F2 fibrosis: 2.55 ± 0.16 vs. F3–F4 fibrosis: 3.61 ± 0.20, P< 0.001). Compared with patients with sustained virological response (SVR), patients without SVR had significantly higher percentages of F3–F4 fibrosis (62.2% vs. 21.6%, P< 0.001) and baseline high viral load (≥600 000 IU/mL; 64.4% vs. 35.6%, P= 0.038). In addition, patients without SVR had significantly higher plasma levels of insulin (15.03 ± 0.89 vs. 10.19 ± 0.55 μU/mL, P< 0.001) and HOMA-IR values (3.76 ± 0.23 vs. 2.50 ± 0.15, P< 0.001). Multivariate analyses showed that F1–F2 fibrosis (odds ratio: 4.49, P= 0.001), HOMA-IR< 2 (odds ratio: 7.15, P= 0.005) and pre-treatment hepatitis C virus RNA< 600 000 IU/mL (odds ratio: 3.26, P= 0.012) were the independent factors associated with SVR.


Insulin resistance is a major determinant of SVR in genotype 1 CHC patients receiving peginterferon α-2b/ribavirin. Strategies to modify insulin resistance may be effective in enhancing SVR before or during anti-viral therapy.

Related Topics

    loading  Loading Related Articles